Significance of antibodies to soluble liver antigen/liver pancreas: A large French study

Liver International

Volumn 29, Issue 6, 2009, Pages 857-864

  Eyraud, Violaine ^a   Chazouilleres, Olivier ^a,b   Ballot, Eric ^a   Corpechot, Christophe ^a   Poupon, Raoul ^a,b   Johanet, Catherine ^a,b  

^a HÔPITAL SAINT ANTOINE   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Antibodies to SLA LP; Diagnostic value; Primary biliary cirrhosis auto immune hepatitis overlap syndrome; Primary sclerosing cholangitis auto immune hepatitis overlap syndrome; Type 1 auto immune hepatitis

Indexed keywords

ACTIN ANTIBODY; AMINOTRANSFERASE; LIVER ANTIGEN; LIVER PANCREAS ANTIBODY; SOLUBLE LIVER ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNE HEPATITIS; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEPATITIS C; HUMAN; JAUNDICE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; SCLEROSING CHOLANGITIS; TOXIC HEPATITIS;

ANTIBODIES; AUTOANTIGENS; BILE DUCT DISEASES; BIOLOGICAL MARKERS; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRANCE; HEPATITIS, AUTOIMMUNE; HUMANS; RETROSPECTIVE STUDIES;

EID: 67049146326     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01986.x     Document Type: Article

References (41)

1. Manns MP, Strassburg CP. Autoimmune hepatitis: Clinical challenges. Gastroenterology 2001; 120: 1502-17.
2. Obermayer-Straub P, Strassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000; 32: 181-97.
3. Czaja AJ, Bianchi AC, Krawitt EL, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41: 207-15.
4. Johnson PJ, Mcfarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
5. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
6. Czaja J, Homburger H. Autoantibodies in liver disease. Gastroenterology 2001; 120: 239-49.
7. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004; 41: 677-83.
8. Manns MP, Gerken G, Kryiatsoulis A, et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987; 1: 292-4.
9. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105: 1522-8.
10. Lohse AW, Gerken G, Mohr H, et al. Relation between autoimmune liver disease and viral hepatitis: Clinical and serological characteristics in 859 patients. J Gastroenterol 1995; 33: 527-33.
11. Nishioka M, Morshed SA, Parveen S, et al. Antibodies to P450IID6, SLA, PDH-E2 and BCKD-E2 in Japanese patients with chronic hepatitis. J Gastroenterol Hepatol 1997; 12: 862-8.
12. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999; 31: 635-40.
13. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: An additional marker in type 1 auto-immune hepatitis. J Hepatol 2000; 33: 208-15.
14. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 1510-15.
15. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/ LP immunoassays: Specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64.
16. Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibodies in Japanese adult patients with autoimmune liver diseases: Analysis with recombinant antigen assay. J Autoimmun 2003; 21: 77-82.
17. Torres-Collado AX, Czaja AJ, Gelpi C. Anti t-RNP(ser)sec/SLA/LP autoantibodies. Comparative study using in-house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of immunoprecipitated RNAs. Liver Int 2005; 25: 410-9.
18. Araiso Y, Palioura S, Ishitani R, et al. Structural insights into RNA-dependent eukaryal and archaeal selenocysteine formation. Nucleic Acids Res 2008; 36: 1187-99.
19. Czaja AJ, Shums Z, Norman GL. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002; 35: 475-83.
20. Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004; 37: 195-201.
21. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
22. Vitozzi S, Djilali-Saiah I, Lapierre P, et al. Anti-soluble liver antigen/liver pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity 2002; 35: 485-92.
23. Vitozzi S, Lapierre P, Djilali-Saiah I, et al. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection. Autoimmunity 2004; 37: 217-22.
24. Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998; 28: 296-301.
25. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001; 49: 589-94.
26. Bedossa P, Poynard T for the Metavir Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
27. Grüber R, Felber E, Pape GR, et al. Detection of antibodies against M2, LKM-1, and SLA in liver diseases by standardized uniform ELISA-techniques. J Clin Lab Anal 1994; 8: 284-92.
28. De Duve C, Pressman BC, Gianetto R, et al. Tissue fractionation studies - 6. Intracellular distribution patterns of enzymes in rat liver tissue. Biochem J 1955; 60: 604-17.
29. Laemmli UK. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
30. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
31. Lohse AW, Hennes E. Diagnostic criteria for autoimmune hepatitis. Hepatol Res 2007; 37: S509.
32. Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: A clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 26: 831-8.
33. Rigopoulou EI, Mytilinaiou M, Romanidou O, et al. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. J Autoimmune Dis 2007; 4: 2.
34. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6: 755-74.
35. Clemente MG, De Virgiliis S. Autoantigen characterization in liver/ kidney microsome positive hepatitis. Digest Liver Dis 2000; 32: 39-45.
36. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993; 38: 744-51.
37. Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 2006; 40: 757-61.
38. Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann NY Acad Sci 2006; 1069: 322-45.
39. Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348: 1399-402.
40. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/ liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-19.
41. Duclos-Vallée JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: Histological recurrence precedes clinical and biochemical recurrence. Gut 2003; 52: 893-7.